Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 9:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Asthma, COPD (Chronic Obstructive Pulmonary Disease)
Interventions: GB-0895 (SC), Placebo (SC); Biological · Drug
Lead sponsor: Generate Biomedicines; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: DeLand, Florida • Miami, Florida • Orlando, Florida + 3 more

Conditions: COVID-19
Interventions: Resveratrol, Vitamin D3; Drug · Dietary Supplement
Lead sponsor: Marvin McCreary, MD; Other
Eligibility: 45 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Schizophrenia
Interventions: Placebo, Lu AF11167; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Glendale, California

Conditions: Schizophrenia, Schizophrenia; Psychosis
Interventions: Xanomeline and Trospium Chloride Capsules, Placebo; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 20
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 15 more

Conditions: Healthy
Interventions: AZD9742, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 23 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Benign Prostatic Hyperplasia
Interventions: Placebo, tadalafil; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 12
States / cities: Huntsville, Alabama • Middlebury, Connecticut • Sarasota, Florida + 9 more

Conditions: Psychological Distress, Psychological Well-being, Subjective Health, Injuries
Interventions: Health and Well-being Committee; Behavioral
Lead sponsor: Massachusetts Institute of Technology; Other
Eligibility: 18 Years and older
Enrollment: 3,459 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Heart Failure, Congestive
Interventions: GSK716155, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 12
States / cities: Savannah, Georgia • Metairie, Louisiana • Auburn, Maine + 9 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV MAT, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years to 49 Years · Female only
Enrollment: 384 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 16
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 13 more

Conditions: Non Small Cell Lung Cancer, Lung Cancer Stage 1
Interventions: Liposomal Bupivacaine, Bupivacaine-Epinephrine; Drug
Lead sponsor: Southern Illinois University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Springfield, Illinois

Conditions: Schizophrenia
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 15
States / cities: Costa Mesa, California • Long Beach, California • Paramount, California + 12 more

Conditions: Liver Fibrosis Due to NASH
Interventions: Placebo, SIM; Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 41
States / cities: Phoenix, Arizona • Coronado, California • San Diego, California + 35 more

Conditions: Chronic Pain, Low Back Pain, Analgesia
Interventions: ALO-02, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 52
States / cities: Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 38 more

Conditions: Acute Limb Ischemia
Interventions: MST-188, Saline; Drug
Lead sponsor: Mast Therapeutics, Inc.; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 4
States / cities: Little Rock, Arkansas • Tampa, Florida • Brooklyn, New York + 1 more

Conditions: Children and Adolescent With Type 2 Diabetes
Interventions: Exenatide Once Weekly, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 16
States / cities: Los Angeles, California • New Haven, Connecticut • Iowa City, Iowa + 13 more

Conditions: Colonoscopy
Interventions: BLI4700, Magnesium bowel preparation; Drug
Lead sponsor: Braintree Laboratories; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 20
States / cities: Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 15 more

Conditions: Rheumatoid Arthritis
Interventions: Secukinumab (AIN457), Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 25
States / cities: Peoria, Arizona • Santa Monica, California • Upland, California + 20 more

Conditions: Venous Leg Ulcers
Interventions: HP802-247, Vehicle; Biological
Lead sponsor: Healthpoint; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 37
States / cities: Phoenix, Arizona • Carlsbad, California • Castro Valley, California + 32 more

Conditions: Cerebrospinal Fluid Leak
Interventions: EVICEL Fibrin Sealant, Hydrogel sealant; Biological · Device
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 13
States / cities: Los Angeles, California • Sacramento, California • Jacksonville, Florida + 10 more

Conditions: Healthy Volunteers
Interventions: AKB-6548 (therapeutic dose), AKB-6548 (supratherapeutic dose), Placebo, Moxifloxacin; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Schizophrenia
Interventions: TAK-063 20 mg, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 15
States / cities: Springdale, Alaska • Culver City, California • Lemon Grove, California + 12 more

Conditions: Seasonal Influenza
Interventions: mRNA-1010, Fluarix®, Influsplit® Tetra, Fluarix Tetra, Alpharix® Tetra; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 40,805 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 188
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 150 more

Conditions: Dry Eye Disease
Interventions: IVW-1001 Ophthalmic Eyelid Wipe; Drug
Lead sponsor: IVIEW Therapeutics Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Fever
Interventions: Ibuprofen 250 mg / Acetaminophen 500 mg, Ibuprofen 250 mg, Acetaminophen 500 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 290 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Knoxville, Tennessee

Search by objective public record fields.

A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD

Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol, a Plant Polyphenol, for COVID-19

Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia

A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days

Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily

Fulfillment Center Study on Work, Health, and Wellbeing

A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure

A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers

Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients

Safety and Efficacy of Cariprazine in Schizophrenia

Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH

A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

Evaluation of MST-188 in Acute Lower Limb Ischemia

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

A Safety and Efficacy Comparison of BLI4700 Bowel Preparation Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy

Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.

Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2

The EVICEL® Neurosurgery Phase III Study

Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers

A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia

A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

Phase 2b Controlled Study

A Study of Ibuprofen 250 mg / Acetaminophen 500 mg Comparing The Antipyretic Effects in Healthy Male Volunteers